Dark

Check out our Level2View

BCAB
BIOATLA INC
stock OTC

EOD

Oct 2, 2026

1.31USD+3.968%(+0.05)3,477

Pre-market

0.00USD-100.000%(-1.26)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 11, 2022

08:36AM EST The Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In Benzinga

Jan 10, 2022

04:07PM EST BioAtla Announces Clinical Collaboration With Bristol Myers Squibb To Study Mecbotamab Vedotin And Ozuriftamab Vedotin In Combination With Opdivo For Treatment Of Solid Tumors Benzinga

04:05PM EST Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo(r) (nivolumab) for Treatment of Solid Tumors PR Newswire

Jan 5, 2022

11:07AM EST Stocks That Hit 52-Week Lows On Wednesday Benzinga

Dec 21, 2021

09:02AM EST BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS PR Newswire

Nov 15, 2021

06:32PM EST BioAlta Reports Q3 Net Loss Of $229M Compared To A Net Loss Of $11.6M YoY Benzinga

05:10PM EST BioAtla Announces Third Quarter 2021 Financial Results And Provides Clinical PR Newswire

Sep 29, 2021

08:14AM EDT BioAtla Announces Private Placement Of 2.7M Shares Priced At $28/Share Benzinga

08:04AM EDT BioAtla Announces Private Placement of 2.7 Million Shares PR Newswire

Aug 13, 2021

05:55PM EDT BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical PR Newswire

Jun 28, 2021

10:21AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021 Benzinga

10:03AM EDT UPDATE: Roth Capital On BioAtla Buy Initiation: Firm Highlights BioAtla Therapies As 'Potentially Having Less Systemic And Off-Target Toxicities And A Broader Therapeutic Index' Than Competitors. Benzinga

08:53AM EDT Roth Capital Initiates Coverage On BioAtla with Buy Rating, Announces Price Target of $75 Benzinga

May 12, 2021

06:27PM EDT BioAtla Announces First Quarter 2021 Financial Results And Provides Business PR Newswire

Mar 26, 2021

08:57AM EDT BTIG Maintains Buy on BioAtla, Raises Price Target to $87 Benzinga

Mar 18, 2021

08:16AM EDT The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq Benzinga

Mar 17, 2021

07:43AM EDT The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes Benzinga

Mar 12, 2021

07:36AM EST The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs Benzinga

Mar 11, 2021

08:19AM EST The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga

Feb 26, 2021

08:17AM EST The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida Benzinga

Feb 18, 2021

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

Feb 16, 2021

06:24AM EST Pfizer Reported Passive Share Stake of 7% in BioAtla Inc in 13G Filing as of December 31, 2020 Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Jan 31, 2021

04:32PM EST Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 14, 2021

07:57AM EST The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates Benzinga

Jan 11, 2021

10:06AM EST Benzinga's Top Upgrades, Downgrades For January 11, 2021 Benzinga

06:01AM EST Credit Suisse Initiates Coverage On BioAtla with Outperform Rating, Announces Price Target of $49 Benzinga

06:00AM EST Jefferies Initiates Coverage On BioAtla with Buy Rating, Announces Price Target of $51 Benzinga

05:58AM EST JP Morgan Initiates Coverage On BioAtla with Overweight Rating, Announces Price Target of $45 Benzinga

05:57AM EST BTIG Initiates Coverage On BioAtla with Buy Rating, Announces Price Target of $47 Benzinga

Jan 9, 2021

01:02PM EST The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off Benzinga

Dec 26, 2020

01:53PM EST Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More Benzinga

Dec 18, 2020

04:00PM EST BioAtla Announces Closing of Initial Public Offering and Full Exercise of the PR Newswire

Dec 16, 2020

12:19PM EST BioAtla Shares Open For Trade At $30.55; IPO Priced At $18/Share Benzinga

09:33AM EST BioAtla Shares Will Open For Quote At 10:10 a.m. EST, Expected To Open For Trade After 10:20 a.m. EST; IPO Priced At $18/Share Benzinga

Dec 15, 2020

08:07PM EST BioAtla Prices IPO Of 10.50 Mln Shares At $18.00/shr RTTNews

08:00PM EST BioAtla Announces Pricing of Initial Public Offering PR Newswire

Share